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Abstract
Secretion of interleukin-10 (IL-10) by CD4+ T cells is an essential immunoregulatory mecha-
nism. The work presented here assesses the role of the signaling molecule protein kinase C
theta (PKCθ) in the induction of IL-10 expression in CD4+ T cells. Using wildtype and PKCθ-
deficient Tg4 T cell receptor transgenic mice, we implemented a well-described protocol of
repeated doses of myelin basic protein (MBP)Ac1-9[4Y] antigen to induce Tr1-like IL-10+ T
cells. We find that PKCθ is required for the efficient induction of IL-10 following antigen
administration. Both serum concentrations of IL-10 and the proportion of IL-10+ T cells were
reduced in PKCθ-deficient mice relative to wildtype mice following [4Y] treatment. We fur-
ther characterized the T cells of [4Y] treated PKCθ-deficient Tg4 mice and found reduced
expression of the transcription factors cMaf, Nfil3 and FoxP3 and the surface receptors PD-
1 and Tim3, all of which have been associated with the differentiation or function of IL-10+ T
cells. Finally, we demonstrated that, unlike [4Y] treated wildtype Tg4 T cells, cells from
PKCθ-deficient mice were unable to suppress the priming of naïve T cells in vitro and in
vivo. In summary, we present data demonstrating a role for PKCθ in the induction of sup-
pressive, IL-10-secreting T cells induced in TCR-transgenic mice following chronic antigen
administration. This should be considered when contemplating PKCθ as a suitable drug tar-
get for inducing immune suppression and graft tolerance.
Introduction
An escalating dose of high-affinity myelin basic protein (MBP)-Ac1-9[4Y] peptide, adminis-
tered subcutaneously (s.c.) to T cell receptor (TCR) transgenic Tg4 mice, induces peripheral
tolerance characterized by the induction of IL-10-secreting CD4+ T cells [1]. These IL-10+ T
cells differentiate along the T helper 1 (Th1) pathway, but convert to a regulatory phenotype as
part of a negative-feedback loop maintaining peripheral tolerance [2]. Several factors including
peptide affinity, dose and solubility and the route of administration used have been shown to
play an important role in the successful induction of IL-10+ T cells [3].
In CD4+ T cells protein kinase C theta (PKCθ) is phosphorylated and activated following
ligation of the TCR by peptide-MHC. Active PKCθ is required for initiation of NFκB-
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dependent transcription therefore naïve CD4+ T cells from PKCθ deficient mice fail to prolif-
erate in response to antigen [4]. PKCθ has also been shown to be specifically required for the
differentiation of autoimmunity-associated T helper 17 (Th17) cells [5] and to inhibit the func-
tion of FoxP3+ regulatory T cells (Treg) [6]. These observations have led some to suggest that
PKCθ represents an attractive drug target for inducing immune suppression in the context of
transplant and autoimmunity [7–9]. However, recent trials of the PKCθ inhibitor sotrastaurin
(AEB071), in renal transplant patients, have demonstrated inferior efficacy compared to exist-
ing regimes [10,11].
As peptide affinity, and thus strength-of-signal from the TCR, are crucial in determining
efficiency of induction of IL-10-secreting T cells from Th1 effector cells [12,13], we hypothe-
sized that altering TCR-mediated signaling by disrupting PKCθ would impact the generation
of IL-10+ T cells, and thus the maintenance of peripheral tolerance, following therapeutic pep-
tide administration. We utilized PKCθ-deficient Tg4 mice (Tg4KO) to study the role of this sig-
naling pathway on the generation of IL-10-secreting T cells and the induction of a tolerant
immune environment following MBP-Ac1-9[4Y] administration.
Materials and methods
Ethical statement
All animal experiments were carried out under the UK Home Office Project Licence number
30/2705 held by David Wraith and the study was approved by the University of Bristol ethical
review committee.
Materials
The acetylated N-terminal peptides of myelin basic protein, MBPAc1-9 [4K] (AcASQKRPS
QR) and [4Y] (AcASQYRPSQR) were synthesized by GL Biochem Shanghai. In vitro stimula-
tions and assays were performed in complete RPMI (Lonza, supplemented with 5% fetal
bovine serum (Biosera), 20mM HEPES, 2mM L-glutamine, 100U/ml penicillin, 100μg/ml
streptomycin and 50mM 2-mercaptoethanol). A list of antibodies and details of their use in
this study can be found in Table 1.
Mice and peptide treatments
PKCθ-deficient Tg4 mice were generated by cross breeding Tg4 mice [14] with B6.129P2-
Prkcqtm1Litt/J mice [4] (originally generated by D. Littman, a gift of A. Poole, Bristol) for at
least 8 generations. Expression of the transgenic Vβ8 TCR and H-2u was confirmed by flow
cytometry and deletion of PKCθ was assessed by PCR of genomic DNA isolated from tail or
ear tissue as described [4]. Tg4WT, Tg4KO and B10.PL mice were bred and maintained under
SPF conditions at the University of Bristol with constant access to water and standard lab
chow. Male and female mice aged 6–14 weeks were used and were equally distributed between
groups based on age and sex. Mice were injected s.c. with PBS or [4Y] peptide in a volume of
200μl of sterile PBS every 3–4 days. [4Y] doses were increased incrementally (0.08, 0.8, 8, 80,
80, 80μg) as previously described [1]. All ex vivo analyses were performed 2 hours after the
final dose of peptide.
Serum cytokine measurements
Peripheral blood samples were taken from the tail vein of mice 2 hours after each s.c. injection
of [4Y] or PBS. Clotted blood was centrifuged at 13,000xg, serum removed and frozen at -20˚C
until analysis. Cytokine concentrations were measured using Murine Th1/Th2 10plex
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FlowCytomixTM Multiplex (eBioscience) according to the manufacturers instructions. Data
was acquired on an LSRII (BD) flow cytometer and analyzed using Flow Cytomix Pro 2.4 soft-
ware (eBioscience).
Cell isolation
Spleens were disaggregated and red blood cells removed by osmotic lysis. Where indicated,
CD4+ T cells were isolated using negative magnetic separation with CD4+ T cell Isolation Kit
II (Miltenyi Biotech) or MagniSort™ Mouse CD4+ T cell Enrichment Kit (eBioscience).
Flow cytometry
Splenocytes were stained with Fixable Viability Dye eFluor1 780 (eBioscience) prior to sur-
face immunostaining. Intranuclear staining (for FoxP3 or cMaf) was performed using FoxP3
Staining Buffers (eBioscience). Intracellular cytokine staining was performed following a 3
hour in vitro stimulation in complete RPMI containing 5ng/ml phorbol 12-myristate 13-ace-
tate (PMA) and 500ng/ml ionomycin (both Sigma-Aldrich) in the presence of GolgiStop (BD
Biosciences). Cytokine staining was performed using Intracellular Fixation Buffer and Permea-
bilization Buffer (eBioscience). Data was acquired on an LSR-II or Fortessa X-20 cytometer
(BD) and analysed using FlowJo (Treestar).
RT-PCR
3-5x106 isolated CD4+ T cells were stimulated for 18 hours with plate-bound anti-CD3 and
anti-CD28 prior to mRNA isolation using an RNeasy Mini Kit, including DNase treatment
(QIAGEN). RNA quality and quantity was assessed using a NanodropTM 2000 (Thermo Fisher
Scientific). Reverse transcription and amplification was carried out using Super-Script III
First-strand Synthesis SuperMix for qRT-PCR (Invitrogen). Real-time PCR was performed
Table 1. Antibodies used in this study.
Epitope Clone Conjugation Supplier Working concentration
CD4 GK1.5 Alexa700 Biolegend 2 μg ml-1
IL-10 ES5-16E3 APC eBioscience 1 μg ml-1
IFNγ XMG1.2 PerCP-Cy5.5 eBioscience 0.5 μg ml-1
IL-4 11B11 PE-Cy7 eBioscience 0.5 μg ml-1
IL-17A TC11-18H10.1 PE eBioscience 1 μg ml-1
IL-2 JES6-5H4 eFluor450 eBioscience 2 μg ml-1
GM-CSF MP1-22E9 FITC eBioscience 2 μg ml-1
cMaf SYMOF1 eFluor660 eBioscience 2 μg ml-1
FoxP3 FJK-16S eFluor450 eBioscience 2 μg ml-1
Lag3 C9B7W APC eBioscience 2 μg ml-1
TIGIT 1G9 APC Biolegend 2 μg ml-1
PD-1 29F.1A12 PE-Cy7 Biolegend 1 μg ml-1
Tim3 8B.2C12 PE eBioscience 1 μg ml-1
CD3ε 2C11 None eBioscience 1 μg ml-1
CD28 37.51 None eBioscience 2 μg ml-1
APC–allophycocyanin.
FITC—fluorescein isothiocyanate.
PE–phycoerythrin.
PerCP—peridinin chlorophyll protein complex.
doi:10.1371/journal.pone.0171547.t001
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with QuantiTect SYBR green RT-PCR kits (QIAGEN) using pre-designed Quanti-Tect Prim-
ers (Maf, QT01063846; NFIL3, QT00265104; Il10, QT00106169; B2m, QT01149547), using an
MJ Opticon Th2 Thermo Cycler (Bio-Rad). The 2-ΔΔCT method was applied to obtain the tar-
get gene expression.
In vitro suppression assay
Splenocytes from Tg4WT and Tg4KO [4Y] and PBS treated mice were cultured in complete
RPMI with 10μg/ml [4K] and 20U/ml rhIL-2 (R&D Systems) at a starting concentration of
1x106 cell/ml. After five days, CD4+ T cells were isolated by magnetic enrichment. Responder
cells were magnetically isolated from naïve Tg4WT mice and labeled with 1mM CellTrace Vio-
let (Life Technologies). 5x105 labeled responder CD4+ T cells, 5x105 suppressor CD4+ T cells
and 1x106 irradiated, sex-matched B10.PL splenocytes (as a source of antigen-presenting cells)
were combined with the indicated concentration of [4K] peptide. Cells were cultured for 72
hours before analysis by flow cytometry. Division indices were computed using FlowJo.
In vivo suppression assay
CD4+ T cells isolated from splenocytes of naïve Tg4WT mice were labeled with 10μM Cell Pro-
liferation Dye eFluor1 450 (eBioscience). 1x107 labeled cells were transferred in a volume of
200μl to PBS or [4Y] treated Tg4WT or Tg4KO mice by intraperitoneal injection. After 48
hours, mice were challenged with 80μg [4Y] s.c. and a further 48 hours later spenocytes were
analyzed by flow cytometry.
Statistical analysis
Graphs were constructed and data tested for statistical significance in GraphPad Prism version
6.0.
Results
Tg4KO mice have lower serum IL-10 levels following s.c. [4Y] treatment
We administered a previously-described regimen of escalating s.c. doses of [4Y] peptide to
Tg4WT and Tg4KO mice (Fig 1A) and measured the concentration of selected cytokines in
peripheral blood serum two hours after each treatment, the point of peak cytokine production
following peptide administration [1,15]. Most strikingly, concentrations of IL-10 were signifi-
cantly (up to 100-fold) lower in Tg4KO mice than Tg4WT (Fig 1B). The serum concentration of
both IFNγ and IL-2 was equivalent in Tg4WT and Tg4KO mice, both showing a peak at the
early 80μg doses which was reduced by the final dose, as shown previously [1] (Fig 1C and
1D). In contrast, serum IL-17A and TNFα concentrations were significantly lower in Tg4KO
mice (Fig 1E and 1F). We observed no significant difference in the number of CD4+ T cells or
the proportion of non-viable cells recovered from spleens of [4Y] treated Tg4WT or Tg4KO
mice (S1 Fig), arguing against differences in T cell expansion or cell death between Tg4WT and
Tg4KO mice as the cause of reduced serum IL-10 concentrations in Tg4KO mice.
Lower proportion of IL-10+ CD4+ T cells and reduced expression of
tolerance-associated markers in [4Y] treated Tg4KO mice
We next sought to further characterize the T cell compartment in Tg4WT and Tg4KO mice
treated with [4Y] or PBS. Intracellular cytokine staining showed no difference in the propor-
tion of splenic CD4+ T cells expressing IL-10, IFNγ, IL-2, IL-4, GM-CSF or IL-17A in Tg4WT
and Tg4KO following PBS treatment. There was also no significant difference in the proportion
PKC theta required for IL-10+ T cell induction
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of IFNγ+, IL-2+, IL-4+, GM-CSF+ or IL-17A+ CD4+ T cells in the spleen of either [4Y] treated
Tg4WT or Tg4KO mice (Fig 2C–2G). In contrast, the proportion of IL-10+ CD4+ T cells among
Tg4KO splenocytes was significantly lower than in Tg4WT (4.1% +/- 0.7 verses 12.6% +/- 1.0),
as was the mRNA expression of il10 in isolated Tg4KO CD4+ T cells (Fig 2B and 2K).
We and others have previously identified transcription factors and cell-surface proteins
associated with tolerance and specifically with IL-10+ CD4+ T cells [1,16]. Following [4Y]
Fig 1. Serum cytokine concentrations in Tg4WT and Tg4KO mice over the course of [4Y] treatment. (A) Experimental design. Escalating
doses of MBPAc1-9[4Y] peptide were administered subcutaneously to mice every 3–4 days. (B-F) Concentrations of IL-10, IL-2, IFNγ, TNFα and
IL-17A in serum from peripheral blood taken two hours after each [4Y] treatment in Tg4WT (open circles) and Tg4KO (closed circles) mice. Plots
show the average of four animals +/- standard error of the mean (SEM) representing one experiment of three performed. *p<0.01 **p<0.001 by
Student’s two-tailed T test.
doi:10.1371/journal.pone.0171547.g001
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treatment, there was a significantly lower proportion of CD4+ T cells expressing the tolerance-
associated transcription factors cMaf and FoxP3 in Tg4KO splenocytes relative to Tg4WT (Fig
2H–2J). Expression of cmaf and nfil3 (e4bp4) mRNA was also approximately 10-fold lower in
isolated CD4+ T cells from [4Y] treated Tg4KO relative to Tg4WT (Fig 2L and 2M).
As previously described [1], the co-inhibitory molecules PD-1, TIGIT, Tim3 and Lag3 were
all induced on Tg4WT CD4+ T cells following treatment with [4Y] (Fig 3). PKCθ-deficiency
affected the expression of these proteins in different ways. Lag3, TIGIT and PD-1 were all
induced on Tg4KO mice following [4Y] treatment (Fig 2), although the proportion of CD4+ T
cells expressing PD-1 was lower in [4Y] treated Tg4KO mice than Tg4WT (Fig 3B). In contrast,
Tim3 was not induced in Tg4KO mice following [4Y] treatment (Fig 3D).
CD4+ T cells from [4Y] treated Tg4KO mice do not suppress naïve T cell
activation
A characteristic of IL-10+ T cells induced by treatment with [4Y] is the ability to suppress the
priming of naïve CD4+ T cells [1,15] and we sought to test the suppressive capacity of Tg4KO
CD4+ cells from [4Y] treated mice. CD4+ T cells from Tg4WT and Tg4KO mice treated with
PBS or [4Y] were first expanded by culturing them for five days with 10μg/ml [4K] and 20U/
Fig 2. Tg4KO mice show reduced induction of IL-10+ T cells and tolerance-associated transcription factors following [4Y]
treatment. (A) Representative flow cytometry plots and plots of all data (B-G) showing production of selected cytokines by splenic CD4+ T
cells from Tg4WT and Tg4KO mice treated with [4Y] or PBS following ex vivo restimulation with PMA and ionomycin. (H) Representative flow
cytometry plots and plots of combined data (I-J) of FoxP3 and cMaf expression in splenic CD4+ T cells from Tg4WT and Tg4KO mice treated
with [4Y] or PBS. All flow cytometry data is gated on live (viability dye-) CD4+ cells. (K-M) Expression of Il10, cmaf and Nfil3 in magnetically-
isolated CD4+ splenocytes from Tg4WT and Tg4KO treated with [4Y], restimulated for 18 hours ex vivo with anti-CD3ε and CD28, as
measured by RT-PCR. Plots F, G, K-M show data from one experiment with 3–4 mice per group. All other plots show the data from two
experiments combined, with a total of 6–8 mice per group. All plots show the mean +/- SEM with each point representing data from one
animal. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, ns p>0.05 assessed by ANOVA with Tukey’s correction for multiple comparisons
(plots B-G and I-J). p values shown in K-M were calculated by two-tailed Student’s T test.
doi:10.1371/journal.pone.0171547.g002
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ml rhIL-2 (as illustrated in Fig 4A). The addition of exogenous IL-2 reverses the anergy of the
tolerant T cells, promoting IL-10 secretion, and previous studies have shown that restimula-
tion is necessary to observe optimal suppressive effects in vitro [15]. The proliferation of [4Y]
treated Tg4WT and Tg4KO cells following restimulation in the presence of IL-2 was equivalent
(S2 Fig). The proportion of IL-10+ CD4+ T cells after expansion is shown in Fig 4B and in each
condition is comparable to the proportion see directly ex vivo (Fig 2B).
The ability of each T cell population to suppress naive T cells responses was assessed by co-
culturing CellTrace Violet labeled naïve Tg4WT CD4+ T cells, expanded CD4+ T cells from
treated mice and irradiated B10.PL (wildtype) splenocytes as a source of antigen presenting
cells at a ratio of 1:1:2 with 0.1, 1 or 10μg/ml [4K] peptide. After 72 hours, the proliferation of
the Tg4WT responders was assessed by flow cytometry (as illustrated in Fig 4A). Tg4WT [4Y]
treated cells significantly suppressed the proliferation of the responder cells relative to Tg4WT
PBS treated cells at all concentrations of antigen tested (Fig 4C and 4D). In contrast, [4Y]
treated Tg4KO cells failed to suppress responder cell proliferation, regardless of the concentra-
tion of antigen. We considered that Tg4KO cells could fail to suppress if they had died upon
restimulation. Analysis of the proportion of live cells recovered at the end of the co-culture
demonstrated that the [4Y] treated Tg4WT and Tg4KO cells were similarly viable following
restimulation (S2B Fig).
Previous work has demonstrated discrepancies between mechanisms of Treg-mediated
suppression when assayed in vitro and in vivo [15]. We therefore tested the suppressive capac-
ity of [4Y] treated Tg4KO cells in vivo. Cell Proliferation Dye-labeled naïve Tg4WT cells were
Fig 3. Tg4KO mice express lower levels of tolerance-associated surface markers following [4Y] treatment. (A) Representative flow cytometry plots and
plots of combined data (B-E) showing production of selected cell surface markers by splenic CD4+ T cells from Tg4WT and Tg4KO mice treated with [4Y] or
PBS. All flow cytometry data is gated on live (viability dye-) CD4+ cells. Shown is the data from two experiments combined, with a total of 6–8 mice per group.
All plots show the mean +/- SEM with each point representing data from one animal. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, ns p>0.05 assessed by
ANOVA with Tukey’s correction for multiple comparisons.
doi:10.1371/journal.pone.0171547.g003
PKC theta required for IL-10+ T cell induction
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adoptively transferred into Tg4WT and Tg4KO mice pre-treated with [4Y] or PBS. After 48
hours, the mice were challenged with 80μg [4Y] and a further 48 hours later the proliferation
of the responder cells recovered from the spleen was assessed by flow cytometry (as illustrated
in Fig 5A). A challenge dose of 80μg of 4Y was chosen as we have demonstrated previously
that suppression observed at this dose of antigen correlates with multiple other measures of
regulatory function, including amelioration of EAE [1]. In PBS-treated Tg4WT mice the pro-
portion of undivided responder cells was 5.9% +/- 0.9 whereas pre-treatment with [4Y]
resulted in significant suppression of the responder cells in Tg4WT mice with 15.0% +/-3.5 of
cells remaining undivided. Pre-treating Tg4KO mice with [4Y] did not induce suppression of
Fig 4. CD4+ T cells from [4Y] treated Tg4KO mice do not suppress the proliferation of naïve Tg4WT T cell in vitro. (A)
Experimental design. Splenocytes from Tg4WT and Tg4KO mice, treated with [4Y] or PBS, were expanded in vitro with
MBPAc1-9[4K] and rhIL-2 for seven days before co-culture with CellTrace-labeled CD4+ T cells isolated from naïve Tg4WT
mice. (B) Examples of the secretion of IL-10 and IFNγ by expanded CD4+ cells from the indicated mice, following restimulation
with PMA and ionomycin. (C, D) Representative flow cytometry data and the computed Division Indices of naïve Tg4WT cells
when stimulated with 0.1, 1 or 10μg/ml [4K] and co-cultured with CD4+ splenocytes from Tg4WT and Tg4KO mice which had
been treated with [4Y] or PBS. Gated on live, CD4+, CellTrace+ cells. All plots show the mean value +/- SEM. Each point
represents data from one [4Y] or PBS-treated mouse assayed individually in vitro and is representative of two experiments.
*p<0.05, **p<0.01, ns p>0.05 assessed by ANOVA with Tukey’s correction for multiple comparisons.
doi:10.1371/journal.pone.0171547.g004
Fig 5. PKCθ is required for induction of a suppressive environment in vivo. (A) Experimental design. Cell Proliferation Dye-labeled CD4+ T cells from
naïve Tg4WT mice were adoptively transferred to Tg4WT and Tg4KO mice, pretreated with [4Y] or PBS. After 48 hours, mice were challenged with 80μg of [4Y]
and the division of the transferred Tg4WT cells was measured by flow cytometry after a further 48 hours. (B) Example flow cytometry data and (C) plotted data
from all mice showing the proportion of transferred Tg4WT cells which remained undivided following [4Y] challenge under each pre-treatment condition. Shown
is the mean +/- SEM. Each data point represents one [4Y] or PBS-treated recipient mouse which were assayed in a single experiment. *p<0.05 assessed by
ANOVA with Tukey’s correction for multiple comparisons.
doi:10.1371/journal.pone.0171547.g005
PKC theta required for IL-10+ T cell induction
PLOS ONE | DOI:10.1371/journal.pone.0171547 February 3, 2017 9 / 14
the transferred responder cells and the proportion of undivided cells in the [4Y] treated Tg4KO
mice was not significantly higher than in PBS-treated Tg4KO mice and was significantly lower
than in [4Y] treated Tg4WT mice (Fig 5B and 5C).
Discussion
The aim of this study was to determine if the signaling protein PKCθ plays a role in the induc-
tion of suppressive IL-10+ T cells during a tolerance induction protocol of self-antigen admin-
istration. IL-10 plays an essential role in the regulation of immune responses and it is therefore
important to understand the mechanisms by which it is induced [17]. Furthermore, if PKCθ is
to be considered a suitable drug target in immune-mediated diseases [7,9], it is essential to
understand the implications that inhibiting this kinase may have on all immunoregulatory
processes.
We demonstrate that PKCθ knock out TCR-transgenic mice fail to upregulate IL-10 follow-
ing the sequential administration of escalating doses of a high-affinity variant of the relevant
cognate antigen, a well-described protocol for the induction of IL-10+ T cells [1,2,18]. Tg4KO
mice show significantly reduced serum concentrations of IL-10 and IL-17A following peptide
treatment, but concentrations of the Th1-associated cytokines IFNγ and IL-2 are equivalent in
Tg4WT and Tg4KO mice. We also observe a reduced proportion of IL-10+ CD4+ splenocytes in
Tg4KO mice compared to Tg4WT, but proportions of IFNγ+ and IL-2+ CD4+ T cells are unaf-
fected by PKCθ deficiency. This is consistent with observations that PKCθ is required for the
differentiation of Th17 but not Th1 cells [5,19]. The transcription factor cMaf is essential for
IL-10 transcription in macrophages and upregulation of cMaf is associated with IL-10 expres-
sion in CD4+ T cells [1,20]. Similarly, FoxP3 and Nfil3 have both been shown to regulate IL-10
transcription [21]. cMaf is strongly induced in [4Y] treated Tg4WT mice, but is not upregulated
in Tg4KO mice CD4+ T cells. FoxP3 is induced in a small proportion of Tg4WT cells, but not in
Tg4KO cells. Similarly, mRNA expression of Nfil3 is approximately 4-fold lower in [4Y] treated
Tg4KO cells compared to Tg4WT. As il10 mRNA levels are also significantly reduced in Tg4KO
cells, it suggests that the transcription factors required to drive expression of IL-10 are not
induced in Tg4KO cells and that this contributes to the reduced levels of IL-10 observed.
The mechanism by which Nfil3 is induced in CD4+ T cells remains unknown. In natural
killer cells, induction of Nfil3 is dependent on 30-phosphoinositide–dependent kinase 1
(PDK1) [22], a known substrate of PKCθ [22,23].This suggests a possible pathway downstream
of PKCθ that could lead to Nfil3 expression in CD4+ T cells. It is similarly unclear what links
PKCθ activation to the induction of cMaf expression. Under conditions favoring the develop-
ment of Th17 cells, induction of cMaf in CD4+ cells is dependent upon Stat3 [24] and PKCθ
has been shown to induce expression of Stat3 via NFκB and AP-1 [5], providing a possible link
between PKCθ and cMaf.
We also observed altered expression of tolerance-associated co-inhibitory molecules in
Tg4KO CD4+ cells following [4Y] treatment. Although PD-1 was induced on Tg4KO CD4+ T
cells, it was on a lower proportion of cells than in Tg4WT mice. Tim3 was not induced on
Tg4KO cells but expression of Lag3 and TIGIT was, on average, unaffected by PKCθ deficiency.
The mechanisms of action and the relative roles of these co-inhibitory receptors is poorly
defined [25], but this data suggest that each may be induced via different stimuli, some depen-
dent of PKCθ and some not. The failure of Tg4KO cells to upregulate Tim3 may be explained
by the deficient Nfil3 expression in these cells as Nfil3 has been shown to be required for Tim3
expression in IL-27-induced regulatory cells [26].
We have previously demonstrated that [4Y] treatment protects Tg4WT and B10.PL non-
TCR transgenic mice from experimental autoimmune encephalomyelitis (EAE) [1]. Due to
PKC theta required for IL-10+ T cell induction
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the impact of PKCθ deficiency on CD4+ T cell priming and Th17 differentiation, PKCθ knock-
out mice are generally resistant to EAE induction [27]. These confounding factors make it dif-
ficult to test the ability of Tg4KO [4Y]-induced IL-10+ T cells to suppress T cell activation in
this disease model. Instead we chose to assess the capacity of these cells to prevent Tg4WT cell
activation in in vitro co-cultures and in an adoptive transfer model of suppression. We demon-
strate that [4Y] treated Tg4KO T cells are unable to suppress the proliferation of naïve Tg4WT
cells in both in vitro in co-cultures and in vivo following adoptive transfer of responder cells to
pre-treated Tg4KO mice. PKCθ is required for efficient FoxP3+ Treg induction [28] and func-
tions to modulate the activity of thymically-derived Treg [6]. Given these observations we can-
not exclude the possibility that altered induction or function of FoxP3+ Treg is responsible for
the reduced suppressive activity we observe in T cells from 4Y-treated Tg4KO mice. However,
we have previously excluded a role for FoxP3+ Treg in suppression following 4Y treatment
[29], supporting our hypothesis that defective IL-10 induction from Tr1-like cells is the cause
of reduced suppression in Tg4KO mice.
We observe that CD4+ T cells from [4Y] treated Tg4KO mice lack only some of the toler-
ance-associated characteristics of [4Y] treated Tg4WT cells (of those measured, specifically IL-
10, cMaf, Nfil3 and Tim3) and this may provide information about which molecules mediate
the cells suppressive ability. Induction of Lag3 and TIGIT is unaffected by PKCθ deficiency,
but the cells are unable to suppress proliferation of the responders, suggesting that these pro-
teins do not play a significant role in the suppression of naïve T cell responses in this system.
When interpreting the experiments presented here it is important to consider the role that
PKCθ plays in all aspects of immune biology and how this may impact the induction of IL-10+
T cells. For example, PKCθ is required for efficient positive selection of T cells in the thymus
[30]. Even in the context of a transgenic TCRαβ a second endogenous α-chain can be selected
and variation in this repertoire as a result of PKCθ deficiency may alter the behavior of CD4+
T cells in the periphery. Until recently, PKCθ expression was believed to be restricted to the
lymphoid lineage. A recent study has described expression of PKCθ mRNA in macrophages
and defined a role for PKCθ in the response of macrophages to infection [31]. This opens the
previously unappreciated possibility that PKCθ-deficiency may impact other aspects of the
myeloid lineage, innate-derived cytokine production and potentially antigen presentation.
This work presented here demonstrates that PKCθ is required for the efficient induction of
IL-10 in effector T cells following administration of an escalating dose of self-antigen to TCR-
transgenic mice. This should be considered when contemplating PKCθ as a suitable drug tar-
get for promoting immune tolerance and the impact of PKCθ inhibitors, including sotras-
taurin, on the induction of IL-10+ CD4 T cells should be investigated.
Supporting information
S1 Fig. Related to Figs 1–3. Tg4WT and Tg4KO mice have a similar number and viability of
CD4+ T cells following [4Y] treatment. (A) The number of CD4+ T cells per spleen in Tg4WT
and Tg4KO mice treated with [4Y] or PBS. (B) The proportion of viability dye (Fixable Viability
Dye eFluor780) positive cells in spleens from Tg4WT and Tg4KO mice treated with [4Y] or
PBS. Both plots show the mean +/- SEM with each point representing data from one animal.
p<0.01, ns p>0.05 assessed by ANOVA with Tukey’s correction for multiple comparisons
(TIF)
S2 Fig. Related to Fig 4. (A) CD4+ T cells from [4Y] treated Tg4WT and Tg4KO expand simi-
larly in response to antigen and IL-2. Splenocytes from Tg4WT and Tg4KO mice treated with
[4Y] were stimulated in vitro with 10μg/ml [4K] peptide +/- 20U/ml rhIL-2 as indicated. Pro-
liferation was measured by incorporation of 3H thymidine, which was added 72 hours after
PKC theta required for IL-10+ T cell induction
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restimulation. The plot shows the mean values from four mice per group, each assayed in trip-
licate (a total of 12 data points per group), +/- SEM. (B) The proportion of viable (Fixable Via-
bility Dye eFluor780 negative) suppressor cells (Cell Proliferation Dye negative, from Tg4WT
or Tg4KO mice treated with PBS or [4Y]) recovered after 72 hours of co-culture with naïve
responder cells and the indicated concentration of [4K] peptide. The plots show the mean val-
ues from 3–4 mice per group +/- SEM. p<0.0001, ns p>0.05 assessed by ANOVA with
Tukey’s correction for multiple comparisons.
(TIF)
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